As I noted a few years ago here, Ferriscan is a niche product,...

As I noted a few years ago here, Ferriscan is a niche product, and is never going to generate a large income on its own. So it might pay the salaries of RHT staff, but you won't get dividends. As I also previously noted, total liver fat is not a particularly useful thing to know, and liver fibrosis is a difficult one to crack, and there are perfectly good cheap non-invasive tests in Fibroscan or shear wave elastography. I see no reason to hold this stock whatsoever, as it is difficult to see how it can ever increase shareholder value.